Absci Corporation (ABSI) reported third-quarter 2026 revenue of $0.3 million and a net loss of $33.3 million, compared with revenue of $0.4 million and a net loss of $28.7 million in the prior-year quarter. Basic and diluted net loss per share was $0.19.
The company said its ABS-201 HEADLINE trial in pattern hair loss remains on track, with 13-week interim proof-of-concept data anticipated in December 2026 and full 26-week data expected in early 2027.
- Research and development expense was $23.6 million, versus $19.2 million a year earlier.
- Selling, general and administrative expense was $9.0 million, versus $8.4 million a year earlier.
- Cash, cash equivalents and marketable securities totaled $173.7 million as of September 30, 2026.
- Absci expects its cash resources to fund operating plans into the second half of 2028.
- The company plans to initiate the Phase 2 STORYLINE trial of ABS-201 for endometriosis in mid-2027.
- Absci appointed former Galderma executive Gerry Muhle as chief commercial officer.
$ABSI Insider Trading Activity
$ABSI insiders have traded $ABSI stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
- MARY T SZELA purchased 12,900 shares for an estimated $148,866
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ABSI Hedge Fund Activity
We have seen 130 institutional investors add shares of $ABSI stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 5,704,820 shares (+inf%) to their portfolio in Q2 2026, for an estimated $66,118,863
- D. E. SHAW & CO., INC. added 5,239,754 shares (+inf%) to their portfolio in Q2 2026, for an estimated $60,728,748
- AMERIPRISE FINANCIAL INC added 3,811,622 shares (+119.9%) to their portfolio in Q2 2026, for an estimated $44,176,698
- TWO SIGMA INVESTMENTS, LP added 2,594,720 shares (+89.5%) to their portfolio in Q2 2026, for an estimated $30,072,804
- BVF INC/IL added 2,361,674 shares (+inf%) to their portfolio in Q2 2026, for an estimated $27,371,801
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,719,992 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $19,934,707
- REDMILE GROUP, LLC removed 1,513,641 shares (-18.3%) from their portfolio in Q2 2026, for an estimated $17,543,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
